Suzhou Zelgen Biopharmaceuticals (688266) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

688266 Suzhou Zelgen Biopharmaceuticals

Watchlist

64.00
+2.59+4.22%

Market Closed Jan 17 15:00 CST

16.94BMarket Cap-97.12P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Zelgen Biopharma Gets Nod to Trial Cancer Drug Combination
MT NewswiresDec 26, 2024 03:07 ET
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Shares Could Be 49% Below Their Intrinsic Value Estimate
Simply Wall StNov 4, 2024 19:59 ET
Health Check: How Prudently Does Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) Use Debt?
Simply Wall StOct 8, 2024 21:42 ET
Zelgen Biopharma Presents Phase 1/2 Data for Antitumor Drug at China Oncology Meet
MT NewswiresSep 26, 2024 04:57 ET
Suzhou Zelgen Biopharmaceuticals' ZG006 Drug Demonstrates Efficacy in Treating Tumors
MT NewswiresSep 8, 2024 22:44 ET
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Market Cap up CN¥744m Last Week, Benefiting Both Individual Investors Who Own 31% as Well as Insiders
Simply Wall StSep 8, 2024 20:10 ET

Comments

Moomoo AI

Feb 5, 2024 17:37

Despite strong revenue, the company's high P/S ratio and weaker forecasted growth may concern investors. High share prices may not be sustainable with expected revenue growth. Business prospects may not significantly improve, posing a risk to share price.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%

Moomoo AI

Dec 22, 2023 04:21

Investor caution is advised as Suzhou Zelgen Biopharmaceuticals' high P/S and less than stellar revenue forecasts could indicate a potential downturn in share price.